Human Menopausal Gonadotropin

Intro

Human Menopausal Gonadotropin (HMG), also called menotropins, is a urinary-derived pharmaceutical extracted from the urine of postmenopausal women.

It contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in approximately a 1:1 ratio — making it the only single-product source of both gonadotropins derived from natural human urine. Commercial brands include Menopur, Repronex, Pergonal, and Merional; the labeled dose per ampoule is typically 75 IU FSH with varying LH content depending on the specific formulation.

HMG was developed in the 1960s for women undergoing assisted reproduction. Its primary medical use remains ovarian stimulation in IVF protocols — daily injections over 7–14 days to drive follicular development before an ovulation trigger. This original IVF application is its established, FDA-approved indication, backed by decades of clinical data and Cochrane-level comparative evidence.

The AAS and TRT community adopted HMG as a fertility-specific adjunct beginning in the late 2000s. The clinical rationale is mechanistically clear: exogenous androgens suppress both LH and FSH via hypothalamic-pituitary negative feedback, producing hypogonadotropic hypogonadism. HCG — which mimics LH — is the standard PCT tool for restoring intratesticular testosterone and testicular volume, but it cannot substitute for FSH. Spermatogenesis requires both FSH acting on Sertoli cells and intratesticular testosterone acting on the same cells — without the FSH component, HCG alone is insufficient for spermatogenesis recovery in a meaningful subset of men.

HMG fills that FSH gap. In men with suppressed FSH from chronic AAS use, HMG 75 IU 2–3x/week alongside HCG delivers both gonadotropin signals, achieving spermatogenesis recovery in the majority of treated cases within 6–18 months. The community use case is: men who want to conceive while on or recovering from TRT/AAS, particularly those who have already tried HCG monotherapy without adequate sperm parameter improvement.

A nuanced issue emerged from community monitoring experience: the LH component of urine-purified HMG is frequently undetectable on standard serum LH immunoassays despite being present in the vial. FSH reliably rises 1–2 mIU/mL above baseline after injection; LH does not register. The leading explanations are that urine-purified LH may have a non-bioidentical molecular structure that standard assays miss, or that rapid metabolic clearance (FSH half-life ~15–20 minutes) prevents detection unless blood is drawn at peak. Practically, serum FSH — not LH — is the reliable potency marker for HMG monitoring.

Observed Effects

Spermatogenesis recovery (men — primary outcome) In men with hypogonadotropic hypogonadism (both idiopathic and AAS-induced), HMG combined with hCG achieves spermatogenesis induction in the majority of cases.

Clinical data shows sperm in the ejaculate (from azoospermia baseline) in 60–80% of patients within 12–18 months. Sperm concentration, progressive motility, and total motile sperm count all improve — the critical parameter for natural conception is progressive motility (defined as sperm that swim in a straight line toward a target), with normal threshold >30%. Community reports confirm this trajectory: from near-zero sperm counts, most men see measurable improvement by 3–6 months with measurable motility improvement by 6–12 months.

Testosterone and hormone panel recovery HMG+hCG therapy restores serum testosterone, estradiol, and gonadotropin levels toward the normal range in gonadotropin-deficient men. Estradiol normalization follows intratesticular testosterone restoration — one documented protocol showed E2 dropping from 86 to 32.9 pg/mL (~62% reduction) over 4 weeks as exogenous testosterone cleared and HMG+HCG took over testicular stimulation.

FSH biomarker response Serum FSH rise after HMG injection is reliably 1–2 mIU/mL above baseline with subcutaneous administration. FSH also serves as an earlier proxy for Sertoli cell activation than waiting months for sperm parameters to move — inhibin B rises with FSH stimulation and is measurable weeks before sperm count changes.

Ovarian stimulation (women — primary clinical indication) In IVF protocols, HMG produces controlled multifollicular development allowing egg retrieval. Cochrane meta-analysis data finds no significant difference in live birth rates between HMG and recombinant FSH for controlled ovarian stimulation — though the rFSH group required more total IU per live birth cycle, suggesting HMG may be more FSH-efficient per ampoule.

What HMG does NOT do HMG cannot restore fertility when the problem is structural (obstructive azoospermia, irreversible testicular damage from prolonged suppression, premature ovarian failure with already-elevated endogenous FSH). It is a stimulant of existing functional tissue — it does not rebuild destroyed Sertoli or Leydig cells.

Field Reports

What works well The HMG+HCG alternating protocol produces the most consistent semen improvement of any community fertility approach.

Users who document their protocols and bloodwork find FSH rising to 4–8 mIU/mL with HMG 75 IU 3x/week, with corresponding improvement in progressive motility over 6–12 months. The documented protocol baseline: progressive motility 17% (well below the >30% reference range) improved toward normal over months with HMG 75 IU TTS + recombinant HCG 1080 IU MWF.

The LH detectability problem — community awareness A widely noted community finding: after HMG injection, serum LH remains undetectable (<0.04 mIU/mL) on standard assays even when blood is drawn 5 minutes post-injection. Multiple brands show this pattern. Users expecting LH elevation as a potency confirmation are frequently confused — the FSH rise (1–2 mIU/mL above baseline) is the only reliable marker. Two working hypotheses: the urine-purified LH has a non-bioidentical structure that escapes standard immunoassay detection, or it is metabolized too rapidly to measure via standard serum timing. The HMG's FSH is functional and detectable; the LH activity is real but unverifiable by standard lab means.

Common mistakes Stacking HCG at high doses expecting synergistic LH effect from the two sources — this results in Leydig desensitization and E2 overshoot without proportional testosterone benefit. Over-AI'ing: some users add anastrozole when E2 rises, not recognizing that intratesticular E2 is essential for spermatogenesis. The correct response to elevated E2 during HMG protocol is to reduce HCG dose, not add an aromatase inhibitor.

What doesn't work HMG cannot overcome structural causes of infertility. Men with varicocele-related sperm damage, obstructive azoospermia, or extensive prior testicular damage from years of high-dose AAS may not respond adequately. After 6 months of standard-dose HMG+HCG with no improvement, the protocol options are: escalate to recombinant FSH/LH, add L-Carnitine, or consult a reproductive urologist for workup.

Injection experience Subcutaneous injection is well-tolerated — similar discomfort level to other subcutaneous peptides. Breast tenderness (from E2 effects) is the most commonly reported minor side effect. No significant injection site reactions reported at standard doses.

Community Consensus

HMG occupies a specific fertility niche in the AAS/TRT community. It is not a general PCT agent; it enters the conversation when semen parameters are the target and hCG or SERMs alone are not enough.

The community divide centers on complexity and cost. hCG is simpler and more familiar for testicular volume and Leydig-cell stimulation, while HMG adds the FSH signal needed for spermatogenesis. Men who have semen analysis data and a concrete fertility goal are the main adopters.

Access patterns often involve urology or reproductive endocrinology because semen analysis and fertility workups naturally pull users toward clinical care. Gray-market use exists, but public article prose should not name brand names, access-route details, or access workarounds.

Risks & Monitoring

HMG's adverse effect profile follows a clear dose-response pattern governed by gonadotropin overstimulation — the same mechanism that provides the benefit becomes a liability when too strong.

Men — Estradiol elevation and gynecomastia The dominant adverse effect in men is E2 overshoot. HMG's LH component (plus the separately administered HCG) drives Leydig cell testosterone production; excess testosterone aromatizes to estradiol. At the standard protocol dose (HMG 75 IU 3x/week + HCG 500–1000 IU 3x/week), most men keep E2 in range. At higher doses or in men with high baseline aromatase activity, E2 elevation causes breast tissue sensitivity, mood effects, and water retention — the same pattern as with high-dose HCG monotherapy. Gynecomastia is reported but uncommon at standard doses.

Leydig cell desensitization At supraphysiological LH-equivalent stimulation (usually from excessive HCG rather than HMG alone), LH receptors on Leydig cells can downregulate. This creates a paradox: more HCG reduces testosterone production. Community protocol wisdom is to keep HCG at 500–1000 IU 3x/week and rely on HMG for the FSH component rather than escalating HCG dose.

Women — Ovarian Hyperstimulation Syndrome (OHSS) OHSS ranges from mild (bloating, ovarian enlargement, minor discomfort — common and manageable) to severe (capillary leak syndrome, thrombosis, respiratory compromise — ~1% of stimulated IVF cycles). OHSS risk is managed by close monitoring (ultrasound follicle count + E2 tracking) and withholding the HCG ovulation trigger if too many follicles develop.

Multiple gestation HMG use in women carries a ~20% multiple gestation rate (majority twins, ~5% triplets or higher-order). This is not OHSS but a separate risk — multiple pregnancy contributes to premature labor risk even when individual follicular development looked appropriate.

Injection site and general Minor injection site discomfort with subcutaneous administration. No hepatotoxicity. No significant cardiovascular signal at fertility doses.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Fertility restoration after AAS/TRT suppression in men. Reported practice uses HMG plus hCG for months, with semen analysis every few months and estradiol monitored. Count, motility, and morphology improve slowly because spermatogenesis is slow.

Fertility maintenance during ongoing TRT. Some men use lower repeated HMG exposure alongside hCG to preserve FSH signaling while testosterone remains suppressive. This is judged by semen parameters, not testicular size alone.

Poor baseline semen parameters. HMG can help when low FSH signaling is part of the problem; it cannot overcome obstructive azoospermia, varicocele damage, or primary testicular failure.

IVF ovarian stimulation in women. This is entirely physician-directed and monitoring-dependent. OHSS risk, follicle count, estradiol, and trigger timing make it unsuitable for public self-protocol instructions.

Dosing Details

Reported HMG use is narrow: male fertility recovery or maintenance when FSH signaling matters, and clinician-managed ovarian stimulation in women.

In men, community and clinical practice commonly pairs HMG with hCG over months, with semen analysis as the real outcome marker. Standard male reports often cluster around 75 IU two or three times weekly, while more severe suppression or azoospermia protocols may use higher specialist-managed exposure.

These are observed patterns, not instructions. The key male risk is overstimulation when HCG and HMG are combined: estradiol overshoot, gynecomastia, and Leydig-cell strain can occur if users chase dose rather than semen and hormone data.

For women, HMG is a fertility medication used in monitored ovarian-stimulation protocols. Dose changes are guided by ultrasound, estradiol, follicle response, and OHSS risk. Unmonitored use is outside the article's safe-use frame.

Stacks & Alternatives

The foundational HMG stack — hCG provides LH-mimicry (Leydig cell stimulation → intratesticular testosterone), HMG provides FSH (Sertoli cell activation → spermatogenesis). Neither alone fully covers both requirements for spermatogenesis. Standard alternating day protocol: hCG MWF, HMG TTS.

Community-standard sperm quality support agent. Injectable L-carnitine 500–1000 mg (pharmaceutical grade) added to HMG+HCG protocols for progressive motility improvement. Antioxidant mechanism — reduces oxidative damage to sperm mitochondria. Frequently combined in fertility protocol community guides.

Escalation option when HMG is unavailable or produces insufficient FSH response. More expensive and less-established in the community, but consistent FSH potency per IU (unlike HMG's variable LH content). Used when HMG fails after 6 months at standard dose.

Some protocols use enclomiphene or clomiphene alongside or sequentially with HMG in men with partial pituitary recovery. SERMs stimulate endogenous FSH/LH release; direct gonadotropin administration (HMG) bypasses the pituitary entirely. Not typically combined simultaneously — used in lighter suppression cases where pituitary function is partially intact.

Alternatives

Stack Cost

Practical Setup

The central practical requirement is knowing what problem is being treated. Elevated baseline FSH suggests primary testicular or Sertoli-cell failure, where adding more FSH-like signal may not work. Low or suppressed FSH with poor semen parameters is the more coherent HMG lane.

For men, semen analysis, FSH, LH/beta-hCG context, total testosterone, estradiol, and symptoms should guide interpretation over months. LH can be confusing on combined hCG/HMG protocols because assay behavior does not always reflect real gonadotropin activity.

For women, HMG should remain inside reproductive-medicine monitoring. Ultrasound follicle tracking, estradiol, trigger timing, and OHSS surveillance are not optional details. Public prose should avoid brand/channel guidance, storage hacks, or reconstitution instructions.

Mechanism Deep Dive

Composition and Source HMG is extracted from the urine of postmenopausal women. After menopause, the ovaries stop producing estrogen and progesterone; the pituitary responds by secreting large amounts of FSH and LH, which appear in the urine. The extraction process concentrates and purifies these two gonadotropins, typically resulting in a ~1:1 FSH:LH product (though exact ratios vary by manufacturer and batch). The urine-purified hormones are structurally identical to endogenous FSH and LH — bioidentical in origin, not biosynthetically produced.

FSH Mechanism of Action FSH binds FSH receptors (FSHR) on Sertoli cells in the seminiferous tubules of the testes (men) and granulosa cells in ovarian follicles (women). In men, FSH activation of Sertoli cells triggers several critical spermatogenic processes: expression of androgen-binding protein (ABP) to concentrate testosterone within the tubule, production of inhibin B (which feeds back to the pituitary to reduce FSH secretion), and structural support for developing sperm cells. FSH acts synergistically with intratesticular testosterone — FSH alone is insufficient for spermatogenesis; it requires the androgen signal provided by Leydig-cell-derived intratesticular testosterone to complete the process. This is why HCG (which drives Leydig cell testosterone) and HMG (which drives Sertoli cell FSH signaling) must work together.

LH Mechanism of Action (and the Urine-Purified LH Problem) The LH component of HMG binds LH/hCG receptors on Leydig cells, stimulating intratesticular testosterone production — the same receptor targeted by HCG. However, the urine-purified LH in HMG has a distinctive practical problem: it is frequently not detected on standard serum LH immunoassays after injection. This is observed across multiple brands and has been documented in real bloodwork data. Two hypotheses: (1) the urine purification process may alter the LH molecule's antigenic epitopes in a way that escapes standard immunoassay detection; (2) FSH's known serum half-life of 15–20 minutes (in pulsatile pituitary secretion context) may apply to urine-derived LH similarly — rapid clearance before the blood draw captures the signal. The practical implication: serum LH is not a reliable monitoring marker for HMG; FSH rise is the validated activity marker.

Pharmacokinetics The labeled half-life of HMG is approximately 32 hours — this is a composite value reflecting the slower pharmacokinetic behavior of FSH at the tissue level (despite rapid serum clearance of the pulsatile component). This long functional half-life explains why 2–3 injections per week maintains biological effect without daily dosing.

Hypogonadotropic Hypogonadism Model Exogenous testosterone suppresses the hypothalamic-pituitary axis through negative feedback: testosterone and estradiol inhibit GnRH secretion from the hypothalamus and LH/FSH release from the pituitary. The result is hypogonadotropic hypogonadism (HH) — low LH, low FSH, low intratesticular testosterone, cessation of spermatogenesis. The testicular apparatus remains functional (Leydig and Sertoli cells are present and capable), but lacks the gonadotropin stimulation signal. HMG+HCG bypasses the suppressed pituitary entirely, delivering gonadotropin signals directly to testicular receptors. Spermatogenesis resumes as FSH re-activates Sertoli cells and HCG/LH re-activates Leydig cells.

Spermatogenic Timeline The full spermatogenic cycle is approximately 74–90 days: 64 days for sperm production in the seminiferous tubules plus 10–14 days for epididymal transport. Any protocol change takes a minimum of one full cycle (~90 days) to appear in ejaculate parameters. This explains why semen analysis every 3 months is standard — monthly analysis before 90 days post-protocol-change cannot capture the full effect of the change.

Inhibin B as Early Marker Inhibin B is produced by Sertoli cells in response to FSH stimulation — it rises before sperm count parameters change, making it a useful early surrogate marker for HMG activity. Rising inhibin B at 4–8 weeks on HMG confirms Sertoli cell activation and predicts eventual spermatogenesis improvement before the 90-day sperm cycle completes.

Progestin Resistance Mechanism Progestins (from nandrolone, trenbolone, or other 19-nor compounds) bind progesterone receptors in the pituitary. This can create resistance to gonadotropin-based fertility protocols — likely via interference with the GnRH/gonadotropin response cascade. The mechanism is distinct from simple androgen suppression, and it explains why men coming off progestogenic AAS may require longer washout before HMG protocols become effective.

Evidence Index